Overall, phenotypic and genotypic changes at the tumor cell and microenvironment levels during sunitinib response and progression are poorly understood, as are the distinct effects of VEGFR-TKIs and mTOR inhibitors on these resistant tumors. This evidence concerns the gene MTOR and neoplasm.